stockrow
Friday 6 November 2026
Export LGND’s income statement to Excel — free account
Ligand Pharmaceuticals Incorporated
LGND Healthcare Biotechnology
Ligand Pharmaceuticals Incorporated’s revenue for fiscal 2025 (year ended December 2025) was $268.1 million, up 60.4% from fiscal 2024.
- Revenue
- −31.8%
- EPS
- −123.9%
- Free cash flow
- −268.5%
- Total debt
- +52.6%
Quarter to September 2026, against a year earlier
306.43
7.43
+2.48%
Follow LGND
Alert me
| Sep '26 | Jun '26 | Mar '26 | Dec '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
120.61 | 31.58 | 25.47 | 30.01 |
+8 more quarters Free account |
P/S ratio |
24.57 | 21.83 | 14.46 | 13.64 | |
P/FCF ratio |
60.32 | 44.23 | 29.50 | 60.02 | |
P/Operating CF |
(226.00) | 264.04 | 81.53 | 79.63 | |
P/B ratio |
6.48 | 6.55 | 3.98 | 3.59 | |
Price to Tangible BV |
13.80 | 9.66 | 5.85 | 5.30 | |
EV/Sales |
25.66 | 21.25 | 13.49 | 12.77 | |
EV/EBITDA |
113.59 | 49.70 | 29.82 | 48.15 | |
EV/Operating CF |
71.55 | 46.88 | 29.98 | 69.35 | |
EV/FCF |
63.00 | 43.07 | 27.50 | 56.19 | |
Quick Ratio |
1.17 | 30.83 | 20.81 | 21.83 | |
Current Ratio |
1.22 | 31.18 | 21.28 | 22.23 | |
Net Debt/EBITDA |
(48.67) | (14.86) | (13.85) | (15.39) | |
Debt/Assets |
30.39% | 51.54% | 29.17% | 28.59% | |
Debt/Equity |
0.71 | 1.16 | 0.45 | 0.44 | |
Asset Turnover |
0.14 | 0.19 | 0.23 | 0.21 | |
Operating CF/Net income |
0.97 | 0.50 | (3.65) | 1.03 | |
Capex/Depreciation |
0.21 | (0.02) | 0.90 | (0.09) | |
Interest Coverage |
(5.44) | 4.91 | 9.94 | 7.50 | |
Research and Development Expense of Revenue |
3.51% | 23.03% | 4.15% | 5.88% | |
Selling, General and Administrative Expense of Revenue |
92.22% | 45.72% | 40.28% | 41.95% | |
Intangible Assets out of Total Assets |
0.23 | 0.14 | 0.21 | 0.21 | |
Share Based Compensation of Revenue |
23.09% | 21.44% | 20.49% | 23.92% | |
Graham Net Nets |
(0.11) | 0.04 | 0.08 | 0.08 | |
Graham Number |
52.99 | 104.22 | 94.06 | 86.35 | |
Earnings Yield |
0.83% | 3.17% | 3.93% | 3.33% | |
Free Cash Flow Yield |
1.66% | 2.26% | 3.39% | 1.67% | |
Revenue per Share |
3.94 | 3.17 | 2.60 | 3.09 | |
Operating CF per Share |
(1.38) | 1.20 | 2.45 | 2.37 | |
Capex per Share |
0.13 | (0.01) | 0.34 | (0.03) | |
Free Cash Flow per Share |
(1.26) | 1.19 | 2.79 | 2.34 | |
Cash per Share |
24.00 | 68.32 | 39.81 | 39.11 | |
Shareholders Equity per Share |
48.18 | 48.22 | 50.16 | 52.60 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
48.18 | 48.22 | 50.16 | 52.60 | |
Free Cash Flow |
(25.09) | 23.87 | 55.44 | 45.31 | |
Working Capital |
107.67 | 1,410.38 | 824.75 | 794.82 | |
Capital Expenditures |
2.50 | (0.14) | 6.75 | (0.61) | |
Net Current Asset Value |
(667.46) | 238.76 | 330.63 | 288.85 | |
EV/EBIT |
276.12 | 65.18 | 39.14 | 83.48 | |
Capex to Sales |
(0.03) | 0.00 | (0.13) | 0.01 | |
Price to Operating Income |
264.35 | 66.94 | 41.97 | 89.17 | |
| Other line items | |||||
Average Receivables |
82.81 | 61.16 | 48.81 | 51.75 | |
Average Payables |
3.89 | 8.99 | 5.32 | 4.24 | |
Average Inventory |
13.20 | 12.88 | 13.94 | 11.62 | |
Average Assets |
1,857.12 | 1,567.24 | 1,218.77 | 1,251.21 | |
Average Common Equity |
955.97 | 898.02 | 896.43 | 923.83 |
Columns are period end dates · fundamentals updated 5 Nov 2026